A Phase 1/1b Study of MEDI3726 in Adults Subjects With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Trial Identifier: D9320C00001
Sponsor: MedImmune, LLC
NCTID:: NCT02991911
Start Date: January 2017
Primary Completion Date: September 2019
Condition: Prostate Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Translation
French Translation
German Translation
Italian Translation

Trial Locations

Country Location
Switzerland Chur, Switzerland, 7000
United Kingdom London, United Kingdom, SM2 5PT
United States of America, CT New Haven, CT, United States of America, 06519
United States of America, FL Sarasota, FL, United States of America, 34232
United States of America, VA Norfolk, VA, United States of America, 23502